Summary
Donald Trump's proposed generic drug tariffs offer Indian drugmakers a two-year duty-free period to adjust manufacturing and supply chain strategies before significant tariff escalations. This window will be crucial for Indian firms to adapt how they serve the US pharmaceutical market.